皮下避孕植入植入市場規模、佔有率和成長分析：按產品類型、荷爾蒙類型、作用持續時間、應用、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球皮下避孕植入市場價值為 12 億美元，預計到 2033 年將從 2025 年的 12.9 億美元成長至 23.2 億美元，預測期（2026-2033 年）複合年成長率為 7.6%。

皮下植入式避孕植入可釋放孕激素長達三年，作為一種低維護、高效的口服避孕藥替代方案，其全球市場正蓬勃發展。這項創新技術不僅能減少意外懷孕，還能降低醫療成本，尤其受到正在將此類技術納入計劃生育計畫的新興國家的關注。人們對長效、可逆避孕方法的興趣日益濃厚，進一步推動了對價格合理、減少就診次數的解決方案的需求。此外，隨著各國政府對國家計劃生育舉措的支持，單次植入即可提供長期避孕效果，植入式避孕植入的使用趨勢也不斷成長。製造商正積極響應市場需求，推出先進的產品，為青少年健康計畫和遠端醫療領域開闢新的成長機會。

全球皮下避孕植入市場的成長要素

由於醫療專業人員的推薦日益增多以及患者對其長期有效性和低維護需求的信心不斷增強，皮下植入式避孕植入的全球市場正蓬勃發展。強調這種可逆、低維護避孕方式便利性的宣傳活動進一步提高了不同族群的認知度和接受度。隨著女性尋求隱藏可靠的避孕方式，臨床醫生在諮詢過程中擴大推薦植入，並將其無縫融入標準的計劃生育流程中。這種協同作用正在形成良性循環，透過提高患者依從性和增強醫療服務提供者的信心來推動市場成長。

全球皮下避孕植入市場的限制因素

全球皮下避孕植入市場面臨許多限制因素，主要源自於各地區監管路徑的差異。全面的臨床數據是滿足安全性和有效性標準的必要條件。申請要求的不一致以及冗長的核准流程阻礙了新產品的市場准入，並抑制了製造商的研發投入。此外，關於長期荷爾蒙暴露指南的變更也帶來了額外的不確定性，迫使企業投入更多資源進行合規性監測。這些挑戰疊加在一起，延長了獲利時間，增加了研發成本，從而限制了市場成長。此外，由於相關人員的談判，認證經常出現延誤，進一步阻礙了創新解決方案的快速推廣應用。

全球皮下避孕植入市場趨勢

全球皮下避孕植入市場正呈現出與數位醫療顯著融合的趨勢，這正在改變生殖健康服務的提供方式。隨著數位平台的普及，醫療服務提供者能夠實現遠距諮詢和有效追蹤植入的使用情況，並透過個人化提醒和遠端醫療諮詢來提高患者的依從性。這種技術主導的方式有助於即時數據分析，使製造商能夠最佳化產品設計，同時簡化保險公司的報銷流程。這種創新浪潮對服務不足的地區尤其有利，它擴大了市場准入，並改善了全球女性的健康。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 宏觀經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 疾病流行病學
• 技術評估

全球皮下避孕植入市場規模：依產品類型分類

• 單桿避孕植入
• 雙桿式避孕植入

全球皮下避孕植入市場規模：依荷爾蒙類型分類

• 依托孕烯植入
• levonorgestrel植入
• 其他

全球皮下避孕植入市場規模：依作用持續時間分類

• 3年內
• 3-5年
• 5年或以上

全球皮下避孕植入市場規模：依應用領域分類

• 長效可逆避孕法（LARC）
• 計劃生育
• 避孕

全球皮下避孕植入市場規模：依最終用戶分類

• 醫院
• 婦科診所
• 門診手術中心

全球皮下避孕植入市場規模：依通路分類

• 醫院藥房
• 零售藥房
• 政府和公共衛生項目

全球皮下避孕植入市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Organon & Co.
• Bayer AG
• Shanghai Dahua Pharmaceutical Co., Ltd.
• Gedeon Richter Plc.
• Theramex HQ UK Limited
• Laboratorios Ariston SA
• Chemo Research SL
• Zydus Lifesciences Limited
• HRA Pharma SAS
• Mithra Pharmaceuticals SA
• HLL Lifecare Limited
• Pregna International Ltd.
• Famy Care Limited
• Janssen Pharmaceuticals, Inc.
• Merck Sharp & Dohme（historical implant portfolio）
• Sichuan Pharmaceutical Co., Ltd.
• CSPC Pharmaceutical Group Limited
• Eurogine SL
• Fuqing Pharmaceutical Group
• Helm AG

結論與建議

Global Subdermal Contraceptive Implants Market size was valued at USD 1.2 Billion in 2024 and is poised to grow from USD 1.29 Billion in 2025 to USD 2.32 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).

The global market for subdermal contraceptive implants, which deliver progestin to prevent pregnancy for up to three years, is gaining momentum as a low-maintenance and effective alternative to oral contraceptives. This innovation not only reduces unintended pregnancies but also lowers healthcare costs, appealing particularly in emerging economies where family planning programs are incorporating such technologies. The rising focus on long-acting reversible contraception is further driving demand for affordable solutions that minimize the need for repeat clinic visits. Additionally, as governments support national family planning initiatives, there's a notable trend towards implants due to their extended protection from a single insertion. Manufacturers are responding with advanced devices, paving the way for growth opportunities in adolescent health programs and remote healthcare settings.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Subdermal Contraceptive Implants market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Subdermal Contraceptive Implants Market Segments Analysis

Global subdermal contraceptive implants market is segmented by product type, hormone type, duration of action, application, end user, distribution channel and region. Based on product type, the market is segmented into Single-Rod Contraceptive Implants and Two-Rod Contraceptive Implants. Based on hormone type, the market is segmented into Etonogestrel Implants, Levonorgestrel Implants and Others. Based on duration of action, the market is segmented into Up to 3 Years, 3-5 Years and Above 5 Years. Based on application, the market is segmented into Long-Acting Reversible Contraception (LARC), Family Planning and Birth Control. Based on end user, the market is segmented into Hospitals, Gynecology Clinics and Ambulatory Surgical Centers. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Government & Public Health Programs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Subdermal Contraceptive Implants Market

The global market for subdermal contraceptive implants is gaining momentum as healthcare providers increasingly endorse these options for their long-lasting effectiveness and low maintenance requirements, which boosts patient confidence in their use. Educational initiatives that emphasize the convenience of reversible, low-maintenance birth control are further promoting awareness and acceptance among various demographics. As women look for discreet and reliable contraceptive solutions, clinicians are more inclined to recommend implants during consultations, integrating them seamlessly into standard family planning practices. This synergy fosters enhanced patient adherence and bolsters provider reassurance, thereby creating a positive feedback loop that drives market growth.

Restraints in the Global Subdermal Contraceptive Implants Market

The global market for subdermal contraceptive implants faces significant restraints due to the varying regulatory pathways across different regions, which necessitate comprehensive clinical data to meet safety and efficacy standards. This inconsistency in submission requirements, coupled with prolonged review processes, can hinder market entry for new products, discouraging manufacturers from investing in their development. Moreover, shifting guidelines surrounding long-term hormonal exposure create additional uncertainty, compelling companies to invest extra resources into compliance monitoring. These challenges collectively restrict market growth by extending the time to revenue and inflating development costs, while negotiations among stakeholders often delay certifications, further impeding the swift adoption of innovative solutions.

Market Trends of the Global Subdermal Contraceptive Implants Market

The Global Subdermal Contraceptive Implants market is witnessing a notable trend toward digital health integration, which is transforming how reproductive health services are delivered. With the rising adoption of digital platforms, providers are now able to offer remote counseling and effective tracking of implant usage, enhancing patient adherence through personalized reminders and telehealth appointments. This technology-driven approach facilitates real-time data analytics, enabling manufacturers to optimize product design while simplifying reimbursement processes for insurers. The influx of such innovations is particularly beneficial in underserved areas, expanding market access and improving health outcomes for women globally.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Disease Epidemiology
• Technology Assessment

Global Subdermal Contraceptive Implants Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Single-Rod Contraceptive Implants
• Two-Rod Contraceptive Implants

Global Subdermal Contraceptive Implants Market Size by Hormone Type & CAGR (2026-2033)

• Market Overview
• Etonogestrel Implants
• Levonorgestrel Implants
• Others

Global Subdermal Contraceptive Implants Market Size by Duration of Action & CAGR (2026-2033)

• Market Overview
• Up to 3 Years
• 3-5 Years
• Above 5 Years

Global Subdermal Contraceptive Implants Market Size by Application & CAGR (2026-2033)

• Market Overview
• Long-Acting Reversible Contraception (LARC)
• Family Planning
• Birth Control

Global Subdermal Contraceptive Implants Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Gynecology Clinics
• Ambulatory Surgical Centers

Global Subdermal Contraceptive Implants Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Government & Public Health Programs

Global Subdermal Contraceptive Implants Market Size & CAGR (2026-2033)

• North America (Product Type, Hormone Type, Duration of Action, Application, End User, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Hormone Type, Duration of Action, Application, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Hormone Type, Duration of Action, Application, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Hormone Type, Duration of Action, Application, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Hormone Type, Duration of Action, Application, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Organon & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Dahua Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gedeon Richter Plc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theramex HQ UK Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratorios Ariston S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chemo Research S.L.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HRA Pharma SAS
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mithra Pharmaceuticals SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HLL Lifecare Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pregna International Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Famy Care Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Sharp & Dohme (historical implant portfolio)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sichuan Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSPC Pharmaceutical Group Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurogine S.L.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fuqing Pharmaceutical Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helm AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations